Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025
Our identification of products anticipated to be selected for negotiation in 2025 (with implementation of negotiated prices in 2027) will help inform manufacturers, payers, patients, and policymakers of the products that will likely see a decrease in Medicare drug prices as result of negotiation. We identified 22 products with levels of spending that are comparable with those anticipated to be selected for negotiation but are not eligible, primarily because of generic or biosimilar availability or insufficient time on market.
Authors
- Inmaculada Hernandez (ORCID: https://orcid.org/0000-0002-0118-4986)
- Nico Gabriel (ORCID: https://orcid.org/0000-0003-1793-2245)
- Ayuri S Kirihennedige
- Emma M. Cousin (ORCID: https://orcid.org/0000-0003-1208-2173)
- Ryan N. Hansen (ORCID: https://orcid.org/0000-0001-5571-6434)
- Sean D. Sullivan
Institutions
- University of Washington (US)
- University of California San Diego (US)
- University of Montana (US)
- London School of Economics and Political Science (GB)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-09-19
- DOI
- https://doi.org/10.18553/jmcp.2024.24167
- Citations
- 6
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 6.78